A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
ABSTRACT Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) contrib- ute to antimicrobial resistance (AMR), a major global public health threat. Furthermore, greater than one third of ICU patients on mechanical ventilation, or with the acute respiratory distress syndrome (ARDS), acquire bac- terial superinfection and develop VABP with attributable mortality due to irreversible lung tissue injury. This A1 RO1 application tests the hypothesis that the targeting of eNAMPT (extracellular nicotinamide phosphoribosyl transferase), a novel DAMP (damage-associated molecular pattern protein) and Toll-like receptor-4 (TLR4) lig- and, may mitigate the risk of developing bacterial superinfection in subjects with HABP and VABP. We speculate that the ALT-100 mAb will serve as an immunomodulatory approach to reduce the severity of lung tissue injury, preserve lung function, and eliminate locus minoris resistentiae to limit bacterial tissue persistence, a risk factor for emergence of AMR. We have shown that eNAMPT is a potent amplifier of innate immunity inflammation and directly contributes to the severity of human/preclinical pneumonia, ARDS, ventilator-induced lung injury (VILI) and sepsis. The ALT-100 mAb proved highly effective in preclinical models of ARDS/VILI/sepsis and recent preliminary interim analysis in a Phase 2A ARDS/VILI clinical trial indicates mAb efficacy. Three Specific Aims will define the value of targeting the eNAMPT/TLR4 signaling cascade in reducing AMR utilizing preclinical mod- els of pneumonia (HABP) and VABP caused by two highly clinically-challenging Gram-negative pathogens, P. aeruginosa (PA) and A. baumanii (AB). SA #1 will expose wild type C57BL/6J mice (+/- ALT-100 mAb), genet- ically-engineered Nampt+/- heterozygous mice, and cNamptec/ec mice (conditional NAMPT KO restricted to endo- thelium) to PA- and AB-induced HABP and VABP. SA #2 will examine the effect of ALT-100 mAb on antibiotic bacterial killing (meropenem, meropenem/tobramycin combination) and explore potential synergistic reductions in lung injury in Swiss Webster (SW) mice exposed to PA- and AB-induced HABP. SA #3 will directly define the microbiological and therapeutic effects of ALT-100 mAb in VABP- exposed SW mice (PA, AB) treated with mero- penem or meropenem/tobramycin. Phenotyping studies will assess antibiotic concentrations, bacterial growth, bacterial killing, resistance emergence, and lung tissue AB/PA protein toxin levels with integration via transla- tional mathematical modeling. We will perform high quality analyses of renal/lung histology, bronchoalveolar lavage (BAL) cell and proteins, blood and lung tissue inflammatory markers and single cell RNA sequencing of lung tissues. These studies, conducted by an team of accomplished investigators with extensive, synergistic expertise (pulmonary medicine, lung pathobiology, antimicrobial pharmacology, translational modeling), will sup- port a novel strategy (in synchrony with the ATS/IDSA guidelines) that addresses the interplay between persis- tent inflammation, immune perturbation and development of antimicrobial resistance (AMR). We endeavor to address the serious societal and medical unmet need to limit the emergence of drug-resistant pathogens.
Grant Summary
A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $861K for university, nonprofit, healthcare org. Applications are due 2031-05-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $861K
2031-05-31
- 1Confirm your organization is eligible for A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia: Frequently Asked Questions
Who is eligible for the A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia?
A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia provide?
A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia provides up to $861K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia deadline?
Applications for A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia are due 2031-05-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia?
To apply for A novel eNAMPT-neutralizing mAb to reduce antimicrobial resistance following hospital- and ventilator-associated bacterial pneumonia, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.